Many investors rightly adopted a wait-and-see attitude when Biopharma Credit (LSE: BPCR) raised $762m in its March 2017 flotation. The prospective return of 8%-9%, including a dividend yield of 6%, looked attractive, but how risky were its returns?
BPCR’s manager, Pharmakon, is a specialist lender to the life-sciences sector, having invested $4.7bn in 40 transactions over 12 years. This, Pharmakon says, is a $1.1trn industry growing at 6% per annum.
The loans to companies are “predominantly secured on approved, commercial-stage products” but the servicing and repayment of the loans is dependent on their success. An average rate of return in double figures implies a material risk of the products not selling.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Thirteen top investments
Pedro Gonzalez de Cosio, CEO of Pharmakon, says that companies have to move fast to capitalise on innovation by spending on research and development (R&D) now. They cannot afford to wait for the cash flow from existing products.
“It’s a race. We, however, are not taking clinical risk. For us, the risk is in projections of future sales from established products. Safety issues and product recalls are very rare and competition from new drugs is highly visible owing to the publication of trial results. With a team of 20, we have the expertise to do the necessary due diligence.”
Four years after flotation, BPCR has made 13 investments, four of which have been repaid with better-than-expected realised returns. The remaining nine are on course to generate annual returns between “high single-digits” and 12%.
A single company, Sarepta, comprises 25% of the portfolio, but it has a market value of $11bn including $1.9bn in cash. “It has $500m of sales at net margins over 70% from three products but has 20 more in the pipeline, so it is spending heavily on R&D.” A fifth of the portfolio is in cash but there is a “very attractive pipeline of deals for 2021”. In 2020, Pharmakon closed just three investments out of 243 screened, but four to six is more normal. The shares trade at $0.97, a 3% discount to net asset value (NAV), and yield 7%.
Another trust, launched in late 2016, that has proved itself is Civitas Social Housing (LSE: CSH). It trades at a 7% premium to NAV, yields 4.7% and has a market value above £700m. It invests in social housing, which it leases to housing associations on long-term, inflation-adjusted terms. These properties are for those in need of “supported living” owing to disabilities, mental-health issues or homelessness. There is a chronic shortage of supply of such accommodation yet local authorities are required to house those in need of it.
Firm foundations
Three housing associations account for 57% of CSH’s income and ten for 94%; 35% of CSH’s balance sheet is financed with low-cost debt but the rental yield of CSH’s portfolio is still around 5.5%, indexed to inflation.
This is expensive finance for housing associations, who have access to much cheaper loans from the public sector. Presumably, their rents are correspondingly elevated but these are paid by the local authority (and indirectly by the government) so they must still offer a good deal compared with the alternatives. CSH investors benefit from the inability or unwillingness of the public sector to drive down the cost of the social housing it is obliged to provide.
It is very hard to see how this could change; there is surely no political appetite to alter the financing structure of the provision of housing to those who can least afford it in order to save the government money. This makes CSH, like BPCR, an attractive long-term proposition for those seeking income plus a bit of capital gain.
-
‘I installed a heat pump in my home – here are five things I’ve learnt’From the size and noise of a heat pump to how much it costs to run one, Ruth Emery reveals what she’s learnt after installing one in her home six months ago
-
3 ways to work out if a stock is good valueThe only thing you can really control in investing is the price you pay for an asset – but how can you tell if you’re getting a good deal when it comes to the price of a stock?
-
Two ways to tap into monopoly profits from airportsMost investors can’t get their hands on airports. Here are two ways you can
-
Fat profits: should you invest in weight-loss drugs?The latest weight-loss treatments could transform public health and the world economy. Should you invest?
-
How investors could profit from Ramsden Holdings' four-part growth strategyRamsdens Holdings offers a diversified set of financial and retail services and a juicy yield, says Dr Michael Tubbs
-
How to invest in the booming insurance marketThe insurance sector is experiencing rapid growth after years of stagnation. Smart investors should buy in now, says Rupert Hargreaves
-
Tap into investment trusts to profit from private equityOpinion The investment companies providing access to unlisted firms’ robust growth are looking cheap, says Max King
-
Out of America's shadow: Why Trump's tariff chaos may be good for non-US stocksOpinion Upending global investment and trade could benefit other countries at the expense of the US market, says Cris Sholto Heaton
-
BP's 'long, painful decline' – and why next year could be even tougherOpinion Long-suffering shareholders in oil giant BP have been pushing for change. It won’t come soon enough, says Matthew Lynn
-
Investment trusts tap the profits in exotic and obscure global marketsOpinion Peter Walls, manager of the Unicorn Mastertrust fund, highlights three investment trusts as he shares where he'd put his money
